Trial Profile
A prospective, single arm, Physician Initiated Trial to assess safety and efficacy of Biolimus A9 Eluting Stent (BES): All-Comers including complex cases sub-group.
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 30 Aug 2016
Price :
$35
*
At a glance
- Drugs Umirolimus (Primary)
- Indications Coronary artery disease; Coronary artery restenosis
- Focus Therapeutic Use
- 03 Jul 2013 New trial record